Cognivue

Cognivue®’s FDA-cleared technology digitally assesses cognitive functioning.

We strive to deliver on our mission to provide cognitive assessment tools to a broad range of healthcare providers for the early detection of cognitive changes.

12/12/2025

Happy ! Today we’re celebrating the incredible people who bring Cognivue's mission to life every day. The images in this grid reflect the spirit of many of the individuals—across the field and behind the scenes—who contribute to our shared commitment to advancing cognitive health. And when it comes to our Sales team, whether they’re on the road, in clinics, supporting practices, or championing cognitive health, each person plays a vital role in bringing meaningful change to both patients and providers.

We’re also proud to celebrate a milestone this year: being named the “Top Cognitive Impairment Early Detection Company of 2025” by Healthcare Tech Outlook. This recognition reflects the hard work of our whole organization, and our sales team is a vital part of that success. Their dedication to partnering with healthcare providers, supporting clinical workflows, and expanding access to cognitive screening continues to drive our momentum and amplify the impact we’re making nationwide.

To our sales professionals: thank you for showing up with heart, resilience, and purpose. Your work strengthens our mission and helps more clinicians bring cognitive health into everyday care. Today, we honor you—and we’re excited for everything we’ll achieve together.

12/10/2025

🧠 Pleased to share our CTAD 2025 poster!
We presented findings on how a two-stage screening strategy using a digital cognitive biomarker (Cognivue Clarity) followed by a blood-based biomarker (LucentAD Complete) helps classify individuals for clinical trial recruitment enrichment and treatment protocols.

🔍 Key findings:
Using the Bio-Hermes study sample, we tested this two-stage approach to mimic how individuals might be evaluated in clinical practice. This strategy classified 85% of individuals into meaningful groups—those likely to have Alzheimer’s disease versus those who do not—leaving only 15% who would require a confirmatory amyloid PET scan.

This cost-effective approach could increase the likelihood of identifying early AD for treatment or trial enrollment, while reducing reliance on costly PET imaging and improving sample enrichment in low-prevalence settings.

Proud to collaborate with Lucent Diagnostics on this important work.

📄 View Poster: https://bit.ly/48SMtUt

12/04/2025

🧠 Live from CTAD 2025!
Great to share our collaborative poster with Lucent Diagnostics, showcasing how a two-stage screening strategy—digital cognitive biomarker + blood-based biomarker—can help drive more efficient Alzheimer’s clinical trial recruitment and support treatment protocols.

It was wonderful having four of the six poster authors on-site and engaging with the scientific community: James E. Galvin, Lindsey Mette, Dave Wilson, and Heather M. Harris.

📸 A few moments from the poster session below!

Cognivue

12/01/2025

👉 Cognivue + Lucent Diagnostics at CTAD 2025!

We’re excited to share that Cognivue and Lucent Diagnostics will be featured together in a poster presentation at the Clinical Trials on Alzheimer’s Disease (CTAD Conference)—highlighting how a digital cognitive biomarker and a blood-based biomarker can be paired in a two-stage screening approach to support more efficient Alzheimer’s clinical trial recruitment.

Poster Details:
📌 Poster | 📍 Indigo Ballroom – Level 2
📅 Wednesday, December 3 | 🕢 7:15 AM – 5:30 PM

Poster Title:
“Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols”

Heading to CTAD? Stop by Poster and view the full findings!

11/24/2025

One of the most powerful aspects of Cognivue’s technology is its use of adaptive psychophysics—a science-driven method that personalizes each assessment in real time.

In our recent webinar, “Measuring What Matters: Integrating Cognitive Assessment into Geriatric Care Pathways,” Dr. Ardeshir Z. Hashmi of the Cleveland Clinic explained it best. In the clip below, he describes how an adaptive test should work:

➡️ If a patient answers correctly, the system increases difficulty—one step at a time.
➡️ When they reach their limit, it confirms that threshold with similar-level tasks.
➡️ That point becomes the patient’s unique cognitive fingerprint, which can be tracked over time.

This is precisely how Cognivue technology works—adapting each assessment in real time, calibrating to a patient’s motor and visual abilities, and adjusting difficulty until it identifies their performance limits.

Watch the full webinar On Demand (link in comments).

11/19/2025

🧠 Cognivue is headed to San Diego for the 2025 Clinical Trials on Alzheimer’s Disease CTAD Conference — taking place December 1-4!

📅 Don’t miss the chance to meet with Dr. James E. Galvin, Chief Scientific Officer, and Heather M. Harris, Sr. VP of Scientific Affairs & Partnerships. Email events@cognivue.com to schedule a meeting.

📍 Catch our poster presentation!
📌 Poster | Wednesday, December 3 | 7:15 AM – 5:30 PM
🧪 “Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols”

We’re looking forward to connecting, collaborating, and contributing to advances in Alzheimer’s clinical research. See you at !

11/11/2025

🧠 Why measure cognitive function? Because what we don’t measure, we can’t manage.

Cognitive changes impact every aspect of aging—from medication safety and mobility to social engagement and care planning. Yet routine cognitive assessment remains underused in clinical practice.

On November 19, join Dr. Ardeshir Z. Hashmi (Cleveland Clinic) and Dr. Joy Siegel (Nova Southeastern University) for forward-looking discussion on advancing geriatric care through earlier, data-driven cognitive assessment and its growing role in value-based care.

📅 November 19, 2025 | 1 PM EST / 10 AM PST
👉 Register now: https://bit.ly/47MsDIQ

Cognivue

11/06/2025

🧠 1 Week Away! Webinar #5 of 5
How do we turn breakthrough research into real-world clinical impact?

On November 13, join James E. Galvin, MD, MPH for the final webinar in our series:
📘 Precision Without Complexity: Cognitive and Amyloid Risk Detection Built for Real-World Clinical Practice

🎥 Register to join live or watch on demand: https://bit.ly/4lVEfOZ

Cognivue

11/04/2025

🌟 Cognivue is heading to Boston for the Gerontological Society of America (GSA) Annual Scientific Meeting — November 12–15!

Visit us at Booth #220 to experience Cognivue Clarity®, our digital cognitive assessment device that provides an objective, comprehensive evaluation of cognitive performance in about 10 minutes.

👋 If you’re attending, stop by to see how our technology supports cognitive health across the aging continuum—from research to real-world care.

10/28/2025

Medication Management is important to your overall health ( )! Reviewing your medications with your healthcare provider or pharmacist is an integral part of medication management. You have the power to optimize your cognition by adopting a combination of key healthy lifestyle habits and being aware of your overall wellness.

10/24/2025

🧠 Final Webinar in Our 5-Part Series | November 13
It all comes together here—turning peer-reviewed evidence into real-world practice with James E. Galvin, MD, MPH, Chief Scientific Officer at Cognivue.

📘 Topic:
Precision Without Complexity: Cognitive and Amyloid Risk Detection Built for Real-World Clinical Practice

This closing session integrates findings from four peer-reviewed Cognivue journal publications—covering psychometric validation, normative ranges, amyloid-risk identification using biomarker-established reference standards, and the Cognivue Amyloid Risk Measure (CARM*).

Dr. Galvin will connect the dots between research and practice, showing how Cognivue Clarity® is designed for real-world clinical workflows:
• Helping clinicians detect cognitive change earlier
• Supporting meaningful conversations with patients and caregivers
• Enabling personalized care pathways that improve outcomes

🎥 Join live or watch on demand: https://bit.ly/3JFbpF9

*patent pending

10/22/2025

Cognivue named “Top Cognitive Impairment Early Detection Solution 2025” and featured as the October Cover Story in Healthcare Tech Outlook.

Cognivue has been recognized by Healthcare Tech Outlook as the Top Cognitive Impairment Early Detection Solution for 2025, further solidifying its leadership in advancing timely cognitive assessment. To highlight the achievement, Healthcare Tech Outlook profiled Cognivue in a four-page cover story in its October issue.

“Too often, cognitive change goes unrecognized until it begins to impact daily life,” said Paul W. Estes, President and CEO of Cognivue. “Cognivue’s FDA-cleared technology is designed to give clinicians practical, objective insight earlier—helping integrate cognitive assessment into routine care. This award reflects our ongoing commitment to research, innovation, and making early detection a reality across healthcare.”

Read the full Healthcare Tech Outlook feature here: ➡️ https://bit.ly/4o1oMP0

Address

7911 Rae Boulevard
Victor, NY
14564

Telephone

+15852031969

Website

https://www.cognivue.com/

Alerts

Be the first to know and let us send you an email when Cognivue posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cognivue:

Shortcuts

Want your practice to be the top-listed Clinic in Victor?

A Path to Cognitive Health and Peace of Mind

Cognivue® is the world’s first FDA-cleared test of cognitive function. Cognivue objectively, quantitatively and reliably identifies changes in cognitive function that could be indicative of an impairment that you may optimally treat or manage. It’s personalized, consistent and reliable.